BriaCell Selling General Administrative from 2010 to 2025

BCTXW Stock  USD 0.10  0.01  9.09%   
BriaCell Therapeutics Selling General Administrative yearly trend continues to be fairly stable with very little volatility. Selling General Administrative is likely to outpace its year average in 2025. During the period from 2010 to 2025, BriaCell Therapeutics Selling General Administrative regression line of quarterly data had mean square error of 2.3 T and geometric mean of  1,614,248. View All Fundamentals
 
Selling General Administrative  
First Reported
2008-07-31
Previous Quarter
1.4 M
Current Value
1.5 M
Quarterly Volatility
665.8 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check BriaCell Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BriaCell Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 18.4 K, Interest Expense of 0.0 or Other Operating Expenses of 40.2 M, as well as many indicators such as Price To Sales Ratio of 0.0, Days Sales Outstanding of 0.0 or Invested Capital of 622.1 K. BriaCell financial statements analysis is a perfect complement when working with BriaCell Therapeutics Valuation or Volatility modules.
  
Check out the analysis of BriaCell Therapeutics Correlation against competitors.

Latest BriaCell Therapeutics' Selling General Administrative Growth Pattern

Below is the plot of the Selling General Administrative of BriaCell Therapeutics Corp over the last few years. It is BriaCell Therapeutics' Selling General Administrative historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BriaCell Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Selling General Administrative10 Years Trend
Slightly volatile
   Selling General Administrative   
       Timeline  

BriaCell Selling General Administrative Regression Statistics

Arithmetic Mean2,978,816
Geometric Mean1,614,248
Coefficient Of Variation101.98
Mean Deviation2,707,619
Median1,334,210
Standard Deviation3,037,812
Sample Variance9.2T
Range7.7M
R-Value0.88
Mean Square Error2.3T
R-Squared0.77
Slope559,101
Total Sum of Squares138.4T

BriaCell Selling General Administrative History

20257.4 M
20247.1 M
20236.2 M
20227.9 M
20217.3 M
20203.7 M
20191.4 M

About BriaCell Therapeutics Financial Statements

BriaCell Therapeutics investors use historical fundamental indicators, such as BriaCell Therapeutics' Selling General Administrative, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BriaCell Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Selling General Administrative7.1 M7.4 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for BriaCell Stock Analysis

When running BriaCell Therapeutics' price analysis, check to measure BriaCell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BriaCell Therapeutics is operating at the current time. Most of BriaCell Therapeutics' value examination focuses on studying past and present price action to predict the probability of BriaCell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BriaCell Therapeutics' price. Additionally, you may evaluate how the addition of BriaCell Therapeutics to your portfolios can decrease your overall portfolio volatility.